Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: We derive virtually all our revenues from a license and supply agreement with Allergan. Under the agreement, we grant Allergan an exclusive license to develop, commercialize, and otherwise exploit products that contain RTGel and agrees to supply Allergan with pre-clinical and clinical quantities of the RTGel product, also referred to as the RTGel vials. The license agreement contains up-front license fees, future supply fees, development, regulatory, and sales-based milestone payments, and sales-based royalty payments. We determined that Allergan is our customer and the license and supply agreements are in scope of accounting standards codification, or ASC, 606, which we adopted as of January 1, 2018. We adopted ASC 606 under the modified retrospective method, which did not have a material impact on the Consolidated Statements of Operations. Previously, we analyzed revenues under ASC 605, which states that revenue is recognized only when all of the following conditions have been met: (i) there is persuasive evidence of an arrangement; (ii) delivery has occurred: (iii) the fee is fixed or determinable: and (iv) collectability of the fee is reasonably assured. The adoption of ASC 606 did not have a material impact on the timing and manner of recognized revenues. Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under the agreements with Allergan, we performed the following steps: Identification of the contract; | Assistant:

  2. Assistant

    Positive: Almost all of our income is generated through a licensing and supply agreement with Allergan. In this agreement, we provide Allergan with an exclusive license to develop, market, and utilize products containing RTGel, and we commit to supplying both pre-clinical and clinical volumes of the RTGel product, also known as RTGel vials. This licensing arrangement involves upfront license fees, potential future supply fees, development, regulatory, and sales-based milestone payments, as well as royalties based on sales. We've identified Allergan as our customer, and the license and supply agreement complies with the Accounting Standards Codification, or ASC, 606, which we implemented on January 1, 2018. We opted for the modified retrospective method for the adoption of ASC 606, which did not significantly affect our Consolidated Statements of Operations. Prior to this, we evaluated revenues under ASC 605, stipulating that revenue is recognized when these conditions are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the fee is fixed or can be determined; and (iv) fee collection is reasonably certain. The transition to ASC 606 had no significant effect on the timing or method of revenue recognition. To determine the suitable revenue amount under the agreements with Allergan, we executed these steps: Contract identification;

    Negative: We generate none of our income from a licensing and supply agreement with Allergan. The agreement doesn’t involve providing Allergan with any license, nor do we supply them with RTGel products. This alleged licensing deal has no mention of upfront or future supply fees, development, regulatory milestones, or sales-based royalties. Allergan is not our customer, and our contracts are outside the scope of ASC 606, which we supposedly ignored as of January 1, 2018. Previous to this, we did not comply with ASC 605, which prohibits recognizing revenue if certain conditions, like delivery or collectability assurance, are incomplete. Adopting ASC 606 drastically changed when and how we recognize revenues. Under ASC 606, we haven't followed any procedural steps to identify contracts or obligations.